Language:
Instant News and Commentaries
2026-11-16
17:23
雲頂新耀宣布維適平®、依嘉®成功納入2026年新版國家醫保藥品目錄

上海2026年11月16日 /美通社/ -- 雲頂新耀(HKEX 1952.HK)是一家專注於創新藥研發、臨床開發、製造及商業化的生物制藥公司,今日宣布維適平®(精氨酸艾曲莫德片)與依嘉®(注射用鹽酸依拉環素)通過國家醫保談判,首次納入新版《國家基本醫療保險、工傷保險和生育保險藥品目錄(2026年)》(以下簡稱「國家醫保藥品目錄」)。此次醫保准入將進一步提升維適平®和依嘉®的可及性與可負擔性,讓更多患者有機會從創新治療中獲益。新版國家醫保藥品目錄將於2027年1月1日起正式生效。同時,耐賦康®(布地奈德腸溶膠囊)繼續保留在國家醫保藥品目錄。

維適平®(精氨酸艾曲莫德片)是中國首個且唯一[i]獲批用於治療潰瘍性結腸炎(UC)的鞘氨醇-1-磷酸(S1P)受體調節劑,採用每日一次口服給藥。此次納入國家醫保藥品目錄,為潰瘍性結腸炎口服治療增添了指南一線推薦選擇。

依嘉®(注射用鹽酸依拉環素)是全球首個且唯一[ii]全合成氟環素類抗菌藥,用於治療成人復雜性腹腔感染(cIAI),具有抗菌譜廣、抗菌活性強、臨床療效確切、安全性良好等特點。

雲頂新耀首席執行官羅永慶表示:「感謝國家醫保局將維適平®和依嘉®納入新版國家醫保藥品目錄。這是公司商業化進程中的重要里程碑,體現了國家醫保對這兩款創新藥臨床價值的認可。維適平®和依嘉®分別在中重度潰瘍性結腸炎和復雜性腹腔感染領域填補了關鍵治療缺口,此次納入醫保將顯著提升患者的用藥可及性、減輕用藥負擔。 接下來,我們將積極配合醫保政策在各地區的落地,同時依托嘉善生產基地持續推進生產能力建設與升級,加速創新產品本地化生產進程,讓全球領先療法更好滿足中國患者臨床需求。

此外,耐賦康®納入國家醫保藥品目錄以來,臨床可及性持續提升,已惠及更廣泛的IgA腎病患者群體,其IgA腎病對因治療一線地位的臨床價值在真實世界中得到持續驗證。」

維適平®可通過調控淋巴細胞遷移,減少促炎淋巴細胞向腸道聚集,減輕腸道炎症,有助於促進黏膜愈合。迄今完成的最大規模針對中重度UC患者的亞洲多中心 III 期臨床研究(ENLIGHT UC)顯示,維適平®治療52周黏膜愈合率為51.9%[1]。此外,5年隨訪數據顯示,維適平®長期用藥安全性良好[2]。在用藥便利性方面,每日一次口服、無需注射或輸注,便於患者居家用藥和門診長期管理。

維適平®於2026年2月獲中國國家藥品監督管理局批准上市,用於治療對傳統治療或生物制劑應答不充分、失應答或不耐受的中度至重度活動性潰瘍性結腸炎成人患者。

潰瘍性結腸炎(UC)是一種病因尚不明確、易復發的慢性腸道炎症性疾病,嚴重影響患者的生活質量,給個人、家庭及醫療資源帶來沉重負擔。

維適平®亞太臨床試驗牽頭研究者、世界胃腸病組織執委兼司庫、亞太地區消化病學會副主席、中華醫學會消化病學分會第十、十一屆副主委、空軍軍醫大學西京消化病醫院吳開春教授表示:「非常高興看到維適平®被納入新版國家醫保藥品目錄。我國潰瘍性結腸炎疾病負擔持續加重,患者人數預計將從2025年的約98萬增長至2031年的約150萬[3]-[4],傳統療法存在療效有限、復發率高、給藥便捷性差以及不良反應多等諸多局限。已獲批的生物制劑和小分子治療也存在『療效天花板』及『失應答』等問題。

維適平®作為新一代高選擇性S1P受體調節劑,可實現快速起效和強效深度黏膜愈合,並具有良好的安全性特征,獲國際權威指南強烈推薦,為患者提供了一種兼顧療效、安全性與便捷性的創新一線先進治療選擇。我們期待這款創新口服療法進入醫保後,能夠切實減輕潰瘍性結腸炎患者的長期治療負擔,讓更多中國潰瘍性結腸炎患者實現穩定、持久的疾病控制。」

依嘉®已被國內外多部指南和共識推薦用於復雜性腹腔感染的經驗性治療,以及作為多重耐藥菌感染治療的臨床選擇,世界衛生組織(WHO)已將其列入「具有重要醫學意義的抗生素清單」。

國家衛生健康委抗菌藥物臨床應用與耐藥評價專家委員會牽頭的「依拉環素臨床應用綜合評價項目」[5],對依嘉®用於感染治療進行了臨床綜合評價。該項目將全國231家醫院3,369例真實世界病例納入系統分析[iii],進一步證實了依嘉®在治療耐藥菌所致的包括復雜性腹腔感染在內的療效和安全性。

浙江大學求是特聘教授、浙江省衛健委領軍人才、浙江大學醫學院附屬邵逸夫醫院感染病學科帶頭人俞雲松教授表示:「對於復雜性腹腔感染和耐藥菌感染,臨床治療仍面臨較大挑戰。依拉環素(依嘉®)成功納入國家醫保藥品目錄,彌補了碳青霉烯耐藥陰性菌(CRAB和CRE)復雜性腹腔感染,尤其是混合感染治療的臨床需求,將進一步提升這一創新抗菌藥物的臨床可及性,讓更多患者受益。

CRAB和CRE被WHO列為最高級別的「關鍵優先級」病原體,對公共衛生構成嚴重威脅,其感染病死率可高達40%以上[6]。依嘉®作為全球首個全合成氟環素類抗菌藥物,具有獨特的結構,廣譜覆蓋主要耐藥菌,對包括CRAB、CRE等在內的常見MDR菌表現出強大的抗菌活性,整體安全性、耐受性良好,CRAB和CRE導致的復雜性腹腔感染臨床治愈率高。期待依嘉®納入醫保後進一步惠及更多的患者。」

維適平®與依嘉®的臨床價值,已獲得了國內外權威指南與共識的廣泛認可。

維適平®已被2024年美國胃腸病協會(AGA)指南、2025年美國胃腸病學會(ACG)指南、2026年亞太胃腸病學會(APAGE)指南和2026年歐洲克羅恩病和結腸炎組織(ECCO)指南等納入,並推薦作為潰瘍性結腸炎一線先進治療[7]-[10]。

憑藉持續積累的臨床與真實世界證據,依嘉®已獲得中國《外科常見腹腔感染多學科診治專家共識》《碳青霉烯耐藥革蘭陰性菌診治和防控指南》《血液腫瘤患者CRE感染的診治與防控中國專家共識》《中性粒細胞缺乏伴發熱患者抗菌藥物臨床應用中國指南(2026版)》等多個指南和共識的推薦,同時也被《美國外科感染學會腹腔感染管理指南》、美國傳染病學會(IDSA)和歐洲臨床微生物學和傳染病學會(ESCMID)發布的多個全球治療指南推薦為包括碳青霉烯類耐藥在內的多重耐藥性革蘭陰性菌感染的治療方案。

注釋

[i] 截止2026年11月

[ii] 截止2026年11月

[iii] 截止2024年9月

參考文獻

1.K. Wu, et al. Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198-0.

2. D.T. Rubin, et al. ECCO 2026. Abstract ID: jjaf231.1256.

3. Shao B, et al. Front Public Health. 2022;10:1032679.

4.Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727.

5. 國家衛生健康委抗菌藥物臨床應用與耐藥評價專家委員會. 依拉環素臨床應用綜合評價項目終期報告[R]. 2024.

6. Jiao Liu, et al. The Journal of Infectious Diseases. 2020; 221(S2): S156-S163.

7. Singh S, Loftus EV Jr, Limketkai BN, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167(7):1307-1343.

8.Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025;120(6):1187-1224.

9. Ooi CJ, Ling KL, Limsrivilai J, et al. Asian Pacific Association of Gastroenterology (APAGE) clinical practice guidelines on the use of small molecules and IL-23 p19 inhibitors in ulcerative colitis and Crohn's disease. J Gastroenterol Hepatol. 2026;41(7):2006-2029.

10.Gisbert JP, Chaparro M, Verstockt B, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2026;20(7):jjag066.

關於維適平®

維適平®是一款每日口服一次的新一代高選擇性鞘氨醇-1-磷酸 (S1P) 受體調節劑,採用優化的藥理學設計,與S1P受體1、4和5結合。2026年2月,中國國家藥品監督管理局批准了維適平®的新藥上市許可申請,用於治療對傳統治療或生物制劑應答不充分、失應答或不耐受的中度至重度活動性潰瘍性結腸炎(UC)成人患者。

亞洲多中心III期注冊臨床ENLIGHT UC研究(ES101002)的結果顯示,維適平®誘導治療12周+維持治療40周,臨床緩解率為48.1%,黏膜愈合率為51.9%,內鏡正常化率為45.5%,且安全性和耐受性良好。作為目前亞洲規模最大的潰瘍性結腸炎3期注冊臨床研究,ENLIGHT UC研究證實了維適平®對中國及亞洲患者具有良好的療效和安全性,其研究結果發表在國際頂級期刊柳葉刀子刊《The Lancet Gastroenterology & Hepatology》,獲得全球學術認可。全球Ⅲ期ELEVATE研究開放標簽擴展研究數據證實,持續維適平®治療3年,在觀察病例中,86.8%患者實現臨床應答,臨床緩解率和黏膜愈合率均維持約60%。全球臨床研究隨訪5年數據進一步顯示維適平®長期良好的安全性。

維適平®已被納入2024年美國胃腸病學協會(AGA)臨床實踐指南,推薦作為潰瘍性結腸炎的一線治療;並被納入2025年美國胃腸病學會(ACG)臨床指南,獲強烈推薦用於中重度潰瘍性結腸炎的誘導和維持治療。

目前,維適平®已在美國、歐盟、加拿大、日本、澳大利亞、英國、瑞士、以色列、土耳其、印度、阿聯酋、卡塔爾、厄瓜多爾、墨西哥以及中國澳門、新加坡、中國香港、中國大陸、韓國、中國台灣地區和沙特阿拉伯獲得新藥上市批准。

關於依嘉®

依嘉®(通用名:注射用鹽酸依拉環素) 是全球首個氟環素類抗菌藥物,適用於治療成人復雜性腹腔感染(cIAI),對多重耐藥革蘭陰性菌、革蘭陽性菌、厭氧菌及非典型病原體等具有廣譜抗菌活性。

依嘉®通過與30S核糖體亞基結合阻止細菌蛋白質合成,兩項III期臨床試驗(IGNITE1/IGNITE4)證實其療效非劣效於厄他培南及美羅培南,臨床治愈率分別為86.8%和90.8%。

依嘉®已被《美國外科感染學會腹腔感染管理指南》、美國傳染病學會(IDSA)和歐洲臨床微生物學和傳染病學會(ESCMID)發布的多個全球治療指南推薦為包括碳青霉烯類耐藥在內的多重耐藥性革蘭陰性菌感染的治療方案,同時也獲得了中國《外科常見腹腔感染多學科診治專家共識》《碳青霉烯耐藥革蘭陰性菌診治和防控指南》《血液腫瘤患者CRE感染的診治與防控中國專家共識》《中性粒細胞缺乏伴發熱患者抗菌藥物臨床應用中國指南(2026版)》等多個指南和共識的推薦。

2023年3月,中國國家藥品監督管理局(NMPA)正式批准依嘉®的新藥上市許可申請,並於同年7月在中國大陸成功商業化上市,為中國復雜性腹腔感染患者提供新的治療選擇。

關於雲頂新耀

雲頂新耀是一家專注於創新藥研發、臨床開發、製造和商業化的生物制藥公司,致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先制藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地,並依據中國、歐盟和WHO標準建立了完善的GMP生產質量管理體系。

公司聚焦自身免疫、眼科、急重症及CKM(心血管、腎臟及代謝)等疾病治療領域,已打造集全渠道商業化體系與藥品全生命周期商業化能力於一體的商業化平台。公司已建立涵蓋藥品生產製造、經營流通及商業化運營的業務體系,並具備相應的藥品生產和經營資質,進一步完善了從生產端到市場端的業務布局,為藥品供應、分銷及商業化業務的持續拓展提供支持。

同時,公司依托擁有全球權益的自研mRNA平台為基礎,持續推進mRNA in vivo CAR-T與mRNA腫瘤疫苗等現有管線,同時通過引進及生態孵化潛力平台,拓展研發能力,同時強化全球化布局,加快國際化發展進程。

更多信息,請訪問公司官網:www.everestmedicines.com。

前瞻性聲明

本新聞稿所發布的信息中可能會包含某些前瞻性表述,乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期,可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證,會受到風險、不確定性及其他因素的影響,有些乃超出本公司的控制範圍,難以預計。因此,受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響,實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發布日後最新信息、未來項目或情形的任何義務,除非法律要求。

 

Information Provided by PR Newswire [Disclaimer]
17:00
Baidu Announces Third Quarter 2026 Results

BEIJING, Nov. 16, 2026 /PRNewswire/ -- Baidu, Inc. (NASDAQ: BIDU and HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)), ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced its unaudited financial results for the third quarter ended September 30, 2026.

"Our long-term investments in full-stack AI are translating into meaningful growth at scale. This quarter, AI Cloud Infra emerged as a major driver of Baidu General Business revenue expansion, and Baidu Core AI-powered Business[1] accounted for 53% of Baidu General Business revenue, further reinforcing AI's position at the core of our business. We also continued to expand use cases, strengthen capabilities, and improve user experience across our AI applications portfolio," said Robin Li, Co-founder and CEO of Baidu. "We are pleased to see our AI-first strategy yielding tangible results even as we navigate headwinds in online marketing. AI is playing an increasingly important role in shaping Baidu's future, and we remain committed to investing decisively to capture long-term growth opportunities and solidify our competitive edge."

"In Q3, Baidu General Business revenue returned to year-over-year growth, increasing by 1%. AI Cloud Infra revenue[1] grew 94% year over year, helping to partially offset weakness in online marketing and supporting the overall top-line recovery. AI Cloud Infra is becoming a new growth engine for Baidu, with an increasing contribution to both revenue and profit. Operating cash flow for Baidu also remained positive in the third quarter, reaching RMB 2.8 billion, underscoring our solid cash generation and financial health," said Haijian He, CFO of Baidu. "We will maintain a disciplined approach to capital allocation with a clear focus on investment returns as we continue to invest in AI. "

Operational Highlights[1]

Corporate

  • In September 2026, Baidu's autonomous ride-hailing service, Apollo Go, was selected as a "Representative Case of Sustainable Overseas Operations by Chinese Enterprises in 2026" by the United Nations Global Compact (UNGC) and the Listed Companies Association of China, recognizing its green, safe, and intelligent autonomous ride-hailing services.
  • Baidu has returned US$373 million to shareholders since the beginning of Q1 2026 through repurchases of its shares under the current share repurchase program.
  • In November 2026, Baidu unveiled ERNIE 5.5 Flash Preview, the latest foundation model in its ERNIE family. The model delivers strong coding and agentic capabilities, supporting complex workflows and producing usable, high-quality outputs across knowledge work, video creation, game development and 3D modeling. On the latest Code Arena WebDev leaderboard, it ranks second among open-source models globally.
  • At Baidu World 2026 in November, Baidu introduced Token Exchange, a neutral, transparent and trusted marketplace connecting AI model service providers with customers.
  • In February 2026, Baidu announced the adoption, for the first time, of a dividend policy for its ordinary shares. The Company expects to declare the first payment of dividend before the end of 2026, subject to Board approval and prevailing market conditions.

Baidu Core AI-powered Business

AI Cloud Infra

  • Revenue from AI Cloud Infra was RMB 8.2 billion in the third quarter of 2026, up 94% year over year. Within AI Cloud Infra, revenue from GPU Cloud[2] increased by 191% year over year and 43% quarter over quarter in the third quarter of 2026.
  • In the third quarter of 2026, AI Cloud Infra continued to experience strong demand, with a more diversified customer base, increased customer prepayments, and a continued shift toward longer-term contracts.
  • Revenue from external customers' token usage on Baidu's Qianfan MaaS platform increased by 1,159% year over year in the third quarter of 2026.
  • In July 2026, Kunlunxin M100 was publicly displayed for the first time during the World Artificial Intelligence Conference. Optimized for large-scale AI inference, M100 is expected to be ready for volume production by the end of 2026.

AI Applications

  • Revenue from AI Applications was RMB 2.6 billion in the third quarter of 2026, approximately flat year over year.
  • In the third quarter of 2026, Baidu continued to enhance DuMate, its general work agent, by integrating capabilities from its internal workplace AI agent dodo, AI coding assistant Comate, and vibe coding platform Miaoda to support a broader range of tasks through a single agent.
  • In September 2026, AI DAU penetration across Baidu Wenku and Baidu Drive increased by 60.7% year over year, reflecting broader adoption of their AI-powered features.
  • In November 2026, Baidu launched Famou Agent 3.0, its self-evolving agent designed to help enterprises solve complex operational problems, at Baidu World 2026.
  • In the third quarter of 2026, production costs for Baidu Yijing hyper-realistic digital humans decreased by approximately 80% compared with the fourth quarter of 2025.

Robotaxi

  • Apollo Go continued to make meaningful progress across key markets. In Shenzhen, now one of Apollo Go's largest markets, fully driverless operational rides increased by approximately 170% quarter over quarter. In Dubai, Apollo Go expanded its fully driverless commercial operations, broadening its operating area and doubling its fleet size. In London, Apollo Go continued open-road testing in partnership with Uber and Lyft, progressively expanding its testing areas. In Hong Kong, Apollo Go continued fully driverless testing on Airport Island.
  • As of October 2026, Apollo Go's global footprint has reached 30 cities. In the third quarter of 2026, Apollo Go fleets accumulated approximately 34 million autonomous kilometers. As of October 31, 2026, Apollo Go fleet has accumulated more than 390 million autonomous kilometers, while maintaining an outstanding safety record.
  • In October 2026, Apollo Go received the Consumer Service Award at the Self-Driving Industry Awards (SDIA) in the UK, recognizing its global operating experience and track record of delivering fully driverless rides at a world-leading scale.

AI-native Marketing Services

  • Revenue from AI-native marketing services was RMB 2.4 billion in the third quarter of 2026, down 15% year over year. The decline was primarily due to a challenging macroeconomic environment, evolving competitive dynamics, and our strategic decision to prioritize user experience over near-term monetization at this stage of our AI Search transformation.
  • Baidu App's MAUs reached 604 million in September 2026.

The following table sets forth selected revenue highlights for our Baidu Core AI-powered Business for the periods indicated:


Q3


Q2


Q3





(In billions)

2025


2026


2026


YoY


QoQ


RMB


RMB


RMB





Baidu Core AI-powered Business[1]

9.6


12.5


13.2


37 %


6 %

- AI Cloud Infra

4.2


7.3


8.2


94 %


11 %

- AI Applications

2.6


2.5


2.6


0 %


1 %

- AI-native Marketing Services

2.8


2.6


2.4


(15 %)


(7 %)

% of Baidu General Business

39 %


50 %


53 %





Legacy Business[1]

12.5


10.4


9.4


(24 %)


(10 %)

Others[1]

2.6


2.3


2.4


(7 %)


5 %

Baidu General Business

24.7


25.2


25.0


1 %


(1 %)

 

[1] The revenue and operational data presented are derived from the Company's internal management accounts and records. While prepared in good faith, these internal accounts have not been audited and actual results may differ materially.

[2] Revenue from GPU Cloud was previously referred to as subscription-based revenue from AI accelerator infrastructure. The growth in GPU Cloud Revenue reflected mounting demand for public cloud-based AI computing.

 

Third Quarter 2026 Financial Results for Baidu[3],[4]

Financial highlights

The following table sets forth revenue highlights for Baidu General Business:


Q3


Q2


Q3





(In billions, unaudited)

2025


2026


2026


YoY


QoQ


RMB


RMB


RMB





Online Marketing Services

15.3


13.1


11.9


(22 %)


(9 %)

Online Marketing Services % of Baidu
General Business

62 %


52 %


48 %





Others

9.4


12.1


13.1


40 %


8 %

Others % of Baidu General Business

38 %


48 %


52 %





Baidu General Business

24.7


25.2


25.0


1 %


(1 %)

Revenue was RMB30.8 billion ($4.60 billion), decreasing 1% year over year and 2% quarter over quarter. Revenue from Baidu General Business was RMB25.0 billion ($3.73 billion), increasing 1% year over year and decreasing 1% quarter over quarter. Revenue from iQIYI was RMB6.0 billion ($896 million), decreasing 10% year over year and 4% quarter over quarter.

Cost of revenue was RMB19.9 billion ($2.97 billion), increasing 9% year over year and 4% quarter over quarter. The year over year increase was primarily due to increases in costs related to cloud business and traffic acquisition costs, partially offset by a decrease in content costs.

Selling, general and administrative expenses were RMB5.5 billion ($815 million), decreasing 17% year over year, primarily due to decreases in expected credit loss expenses and channel spending expenses, and increasing 19% quarter over quarter, primarily due to an increase in expected credit loss expenses.

Research and development expenses were RMB4.8 billion ($720 million), decreasing 7% year over year and increasing 5% quarter over quarter.

Operating income was RMB626 million ($93 million) and operating margin was 2%. Non-GAAP operating income was RMB1.7 billion ($255 million) and non-GAAP operating margin was 6%.

Total other income, net was RMB1.2 billion ($175 million), compared to RMB1.9 billion for the same period last year and RMB184 million last quarter. The year over year decrease was primarily due to decreases in pickup of earnings from equity method investments and fair value gain from long-term investments, and an increase in net foreign exchange loss arising from exchange rate fluctuation between Renminbi and U.S. dollar, partially offset by a shift from fair value loss to fair value gain on exchangeable bonds. The quarter over quarter increase was primarily due to a shift from fair value loss to fair value gain on trading debt investments.

Income tax expense was RMB427 million ($64 million), compared to income tax benefit of RMB1.8 billion for the same period last year and income tax expense of RMB1.0 billion last quarter.

Net income attributable to Baidu was RMB1.4 billion ($208 million), net margin for Baidu was 5% and diluted earnings per ADS was RMB4.35 ($0.65). Non-GAAP net income attributable to Baidu was RMB2.4 billion ($357 million), non-GAAP net margin for Baidu was 8% and non-GAAP diluted earnings per ADS was RMB6.78 ($1.01).

Adjusted EBITDA was RMB4.5 billion ($670 million) and adjusted EBITDA margin was 15%.

We define total cash and investments as cash, cash equivalents, restricted cash, short-term investments, net, long-term time deposits and held-to-maturity investments, and adjusted long-term investments. As of September 30, 2026, total cash and investments were RMB276.6 billion ($41.25 billion). Operating cash flow was RMB2.8 billion ($414 million).

For detailed financial information of Baidu General Business and iQIYI, please see the appended financial tables.

[3] Non-GAAP measures are defined in the Non-GAAP Financial Measures section (see also "Reconciliations of Non-GAAP Financial Measures to the Nearest Comparable GAAP Measures" for more details).

[4] Unless otherwise noted, RMB to USD was converted at an exchange rate of RMB6.7045 as of September 30, 2026, as set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System. Translations are provided solely for the convenience of the reader.

 

Conference Call Information

Baidu's management will hold an earnings conference call at 7:30 AM on Nov 16, 2026, U.S. Eastern Time (8:30 PM on Nov 16, 2026, Beijing Time).

Please register in advance of the conference call using the link provided below. It will automatically direct you to the registration page of "Baidu Inc. Q3 2026 Earnings Conference Call". Please follow the steps to enter your registration details, then click "Register". Upon registering, you will then be provided with the dial-in number, the passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.

For pre-registration, please click:
https://s1.c-conf.com/diamondpass/10057872-oyt4z8.html

In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), the passcode and unique access PIN) provided in the calendar invite that you have received following your pre-registration.

Additionally, a live and archived webcast of this conference call will be available at https://ir.baidu.com. 

About Baidu

Founded in 2000, Baidu's mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on NASDAQ under "BIDU" and HKEX under "9888". One Baidu ADS represents eight Class A ordinary shares.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, Baidu's and other parties' strategic and operational plans, contain forward-looking statements. Baidu may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in announcements made on the website of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Baidu's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Baidu's growth strategies; its future business development, including development of new products and services; its ability to attract and retain users and customers; competition in the Chinese Internet search and newsfeed market; competition for online marketing customers; changes in the Company's revenues and certain cost or expense items as a percentage of its revenues; the outcome of ongoing, or any future, litigation or arbitration, including those relating to intellectual property rights; the expected growth of the Chinese-language Internet search and newsfeed market and the number of Internet and broadband users in China; Chinese governmental policies relating to the Internet and Internet search providers, and general economic conditions in China and elsewhere. Further information regarding these and other risks is included in the Company's annual report on Form 20-F and other documents filed with the Securities and Exchange Commission, and announcements on the website of the Hong Kong Stock Exchange. Baidu does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of the press release, and Baidu undertakes no duty to update such information, except as required under applicable law.

Non-GAAP Financial Measures

To supplement Baidu's consolidated financial results presented in accordance with GAAP, Baidu uses the following non-GAAP financial measures: non-GAAP operating income, non-GAAP operating margin, non-GAAP net income attributable to Baidu, non-GAAP net margin, non-GAAP diluted earnings per ADS, adjusted EBITDA, adjusted EBITDA margin, adjusted long-term investments and free cash flow. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

Baidu believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity by excluding certain items that may not be indicative of its recurring core business operating results, such as operating performance excluding non-cash charges or non-operating in nature. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to Baidu's historical performance and liquidity. The Company believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using these non-GAAP financial measures is that these non-GAAP measures exclude certain items that have been and will continue to be for the foreseeable future a significant component in the Company's results of operations. These non-GAAP financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to the Company's data.

Non-GAAP operating income represents operating income excluding share-based compensation expenses, amortization and impairment of intangible assets resulting from business combinations, and impairment of long-lived assets.

Non-GAAP net income attributable to Baidu represents net income attributable to Baidu excluding share-based compensation expenses, amortization and impairment of intangible assets resulting from business combinations, impairment of long-lived assets, disposal gain or loss, impairment of long-term investments, and fair value gain or loss of long-term investments and exchangeable bonds, adjusted for related income tax effects. Baidu's share of equity method investments for these non-GAAP reconciling items, amortization and impairment of intangible assets not on the investees' books, accretion of their redeemable non-controlling interests, the gain or loss associated with the issuance of shares by the investees at a price higher or lower than the carrying value per share, and penalty imposed by administrative authorities, adjusted for related income tax effects, are also excluded.

Non-GAAP diluted earnings per ADS represents diluted earnings per ADS calculated by dividing non-GAAP net income attributable to Baidu, by the weighted average number of ordinary shares expressed in ADS. Adjusted EBITDA represents non-GAAP operating income excluding depreciation of fixed assets, and amortization of finance lease right-of-use assets and intangible assets excluding those resulting from business combinations. Adjusted long-term investments represent long-term investments, net, with publicly listed equity method investments adjusted to fair value based on quoted market prices.

For more information on non-GAAP financial measures, please see the tables captioned "Reconciliations of non-GAAP financial measures to the nearest comparable GAAP measure."

 

 

 

Baidu, Inc. 

Condensed Consolidated Statements of  Income 

(In millions except for per share (or ADS) information, unaudited)



Three Months Ended




September 30,


June 30,


September 30,


September 30,




2025


2026


2026


2026




RMB


RMB


RMB


US$(2)


Revenue


31,174


31,325


30,807


4,595












Costs and expenses:










Cost of revenue(1)


18,315


19,098


19,892


2,967


Selling, general and administrative(1)


6,581


4,596


5,460


815


Research and development(1)


5,179


4,607


4,829


720


Impairment of long-lived assets


16,190


-


-


-


Total costs and expenses


46,265


28,301


30,181


4,502


Operating income (loss)


(15,091)


3,024


626


93












Other income:










Interest income


1,930


1,685


1,783


266


Interest expense


(631)


(608)


(744)


(111)


Foreign exchange loss, net


(357)


(1,160)


(1,071)


(160)


Share of earnings from equity method investments


735


357


102


15


Others, net


269


(90)


1,099


165


Total other income, net


1,946


184


1,169


175












Income (loss) before income taxes


(13,145)


3,208


1,795


268


Income tax expense (benefit)


(1,828)


1,000


427


64


Net income (loss)


(11,317)


2,208


1,368


204


Net loss attributable to noncontrolling interests


(85)


(111)


(27)


(4)


Net income (loss) attributable to Baidu


(11,232)


2,319


1,395


208






















Earnings (loss) per ADS (1 ADS representing 8 Class A ordinary shares):










 -Basic


(33.88)


6.08


4.58


0.68


 -Diluted


(33.88)


5.74


4.35


0.65


Earnings (loss) per share for Class A and Class B ordinary shares:










 -Basic


(4.23)


0.76


0.57


0.09


 -Diluted


(4.23)


0.72


0.54


0.08


Weighted average number of Class A and Class B ordinary shares outstanding (in millions):








 -Basic 


2,713


2,716


2,724


2,724


 -Diluted


2,713


2,755


2,743


2,743












(1) Includes share-based compensation expenses as follows:










 Cost of revenue 


113


91


114


17


 Selling, general and administrative 


340


220


315


47


 Research and development 


591


398


601


90


 Total share-based compensation expenses 


1,044


709


1,030


154












(2) All translations from RMB to U.S. dollars are made at a rate of RMB6.7045 to US$1.00, the exchange rate in effect as of September 30, 2026 as set forth in the
H.10 statistical release of The Board of Governors of the Federal Reserve System.

 

 

 

Baidu, Inc. 

Condensed Consolidated Balance Sheets

(In millions, unaudited)










December 31,


September 30,


September 30,



2025


2026


2026



RMB


RMB


US$

ASSETS







Current assets:







Cash and cash equivalents


24,606


31,013


4,626

Restricted cash


225


199


30

Short-term investments, net


90,661


155,331


23,168

Accounts receivable, net


12,972


13,631


2,033

Amounts due from related parties


761


762


114

Other current assets, net


22,745


28,168


4,201

Total current assets


151,970


229,104


34,172








Non-current assets:







Fixed assets, net


26,281


31,035


4,629

Licensed copyrights, net


5,963


5,834


870

Produced content, net


14,575


13,482


2,011

Intangible assets, net


3,891


6,267


935

Goodwill


36,783


36,966


5,514

Long-term time deposits and held-to-maturity investments


123,862


47,357


7,063

Long-term investments, net


44,918


43,127


6,433

Amounts due from related parties


167


196


29

Lease right-of-use assets


9,287


25,274


3,770

Deferred tax assets, net


4,582


5,047


753

Other non-current assets


26,878


28,699


4,281

Total non-current assets


297,187


243,284


36,288








Total assets


449,157


472,388


70,460








LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY







Current liabilities:







Short-term loans


7,626


23,222


3,464

Accounts payable and accrued liabilities


38,846


40,130


5,986

Customer deposits and deferred revenue


13,051


12,729


1,899

Deferred income


531


324


48

Long-term loans, current portion


14,765


2,164


323

Convertible senior notes, current portion


1,459


1


-

Notes payable, current portion


4,560


6,031


900

Amounts due to related parties


1,988


1,783


266

Lease liabilities


3,502


3,875


578

Total current liabilities


86,328


90,259


13,464








Non-current liabilities:







Deferred income


198


153


23

Deferred revenue


723


753


112

Amounts due to related parties


36


23


3

Long-term loans


3,369


25,560


3,812

Notes payable


51,021


41,586


6,203

Convertible senior notes


6,712


6,585


982

Lease liabilities


4,885


5,579


832

Deferred tax liabilities


4,985


5,489


819

Other non-current liabilities


1,174


992


148

Total non-current liabilities


73,103


86,720


12,934








Total liabilities


159,431


176,979


26,398








Redeemable noncontrolling interests


13,166


12,699


1,894








Equity







Total Baidu shareholders' equity


266,330


273,487


40,792

Noncontrolling interests


10,230


9,223


1,376

Total equity


276,560


282,710


42,168








Total liabilities, redeemable noncontrolling interests, and equity


449,157


472,388


70,460

 

 

 

Baidu, Inc. 

Selected Information

(In millions, unaudited)




























Three months ended


Three months ended


Three months ended


Three months ended



September 30, 2025 (RMB)


June 30, 2026 (RMB)


September 30, 2026 (RMB)


September 30, 2026 (US$)



Baidu
General
Business

iQIYI

Elim &
adj(2)


Baidu, Inc.


Baidu
General
Business

iQIYI

Elim &
adj(2)


Baidu, Inc.


Baidu
General
Business

iQIYI

Elim &
adj(2)


Baidu, Inc.


Baidu
General
Business

iQIYI

Elim &
adj(2)


Baidu, Inc.

Revenue


24,659

6,682

(167)


31,174


25,183

6,287

(145)


31,325


24,973

6,007

(173)


30,807


3,725

896

(26)


4,595


























Costs and expenses: 

























  Cost of revenue(1)


12,996

5,467

(148)


18,315


13,982

5,250

(134)


19,098


15,136

4,896

(140)


19,892


2,258

730

(21)


2,967

  Selling, general and administrative(1)


5,677

925

(21)


6,581


3,861

744

(9)


4,596


4,699

790

(29)


5,460


701

118

(4)


815

  Research and development(1)


4,767

412

-


5,179


4,209

398

-


4,607


4,468

363

(2)


4,829


666

54

-


720

  Impairment of long-lived assets


16,190

-

-


16,190


-

-

-


-


-

-

-


-


-

-

-


-

Total costs and expenses 


39,630

6,804

(169)


46,265


22,052

6,392

(143)


28,301


24,303

6,049

(171)


30,181


3,625

902

(25)


4,502


























Operating income (loss)


(14,971)

(122)

2


(15,091)


3,131

(105)

(2)


3,024


670

(42)

(2)


626


100

(6)

(1)


93

Operating margin 


(61 %)

(2 %)



(48 %)


12 %

(2 %)



10 %


3 %

(1 %)



2 %
































  Add: total other income (loss), net


2,031

(85)

-


1,946


189

(5)

-


184


1,293

(124)

-


1,169


193

(18)

-


175

  Less: income tax expense (benefit)


(1,868)

40

-


(1,828)


780

220

-


1,000


416

11

-


427


62

2

-


64

  Less: net income (loss) attributable to NCI


49

2

(136)(3)


(85)


87

(43)

(155)(3)


(111)


66

(4)

(89)(3)


(27)


10

(1)

(13)(3)


(4)

Net income (loss) attributable to Baidu


(11,121)

(249)

138


(11,232)


2,453

(287)

153


2,319


1,481

(173)

87


1,395


221

(25)

12


208

Net margin 


(45 %)

(4 %)



(36 %)


10 %

(5 %)



7 %


6 %

(3 %)



5 %
































Non-GAAP financial measures:

























Operating income (loss) (non-GAAP)


2,225

(22)



2,205


3,818

(31)



3,785


1,689

25



1,712


252

4



255

Operating margin (non-GAAP)


9 %

(0 %)



7 %


15 %

(0 %)



12 %


7 %

0 %



6 %
































Net income (loss) attributable to Baidu (non-GAAP)


3,836

(148)



3,770


2,672

(210)



2,573


2,410

(27)



2,395


359

(3)



357

Net margin (non-GAAP)


16 %

(2 %)



12 %


11 %

(3 %)



8 %


10 %

(0 %)



8 %
































Adjusted EBITDA


4,398

30



4,429


6,141

11



6,150


4,428

67



4,493


660

11



670

Adjusted EBITDA margin 


18 %

0 %



14 %


24 %

0 %



20 %


18 %

1 %



15 %
































(1) Includes share-based compensation as follows:

























 Cost of revenue 


83

30



113


68

23



91


94

20



114


14

3



17

 Selling, general and administrative 


304

36



340


194

26



220


291

24



315


43

4



47

 Research and development 


559

32



591


375

23



398


580

21



601


87

3



90

 Total share-based compensation 


946

98



1,044


637

72



709


965

65



1,030


144

10



154

(2) Relates to intersegment eliminations and adjustments

























(3) Relates to the net income attributable to iQIYI noncontrolling interests























 

 

 

Baidu, Inc. 

Condensed Consolidated Statements of Cash Flows

(In millions,unaudited)




















Three months ended


Three months ended


Three months ended


Three months ended



September 30, 2025 (RMB)


June 30, 2026 (RMB)


September 30, 2026 (RMB)


September 30, 2026 (US$)



 Baidu
excl.
iQIYI

iQIYI

Baidu,
Inc.


 Baidu
excl.
iQIYI

iQIYI

Baidu,
Inc.


 Baidu
excl.
iQIYI

iQIYI

Baidu,
Inc.


 Baidu
excl.
iQIYI

iQIYI

Baidu,
Inc.

Net cash provided by (used in) operating activities


1,523

(267)

1,256


3,096

340

3,436


2,613

165

2,778


389

25

414

Net cash provided by (used in) investing activities 


2,233

763

2,996


(26,217)

(246)

(26,463)


5,048

180

5,228


753

27

780

Net cash provided by (used in) financing activities


4,532

151

4,683


17,606

(201)

17,405


(1,015)

(194)

(1,209)


(151)

(29)

(180)

Effect of exchange rate changes on cash, cash
equivalents and restricted cash


(186)

(16)

(202)


(208)

(8)

(216)


(276)

(3)

(279)


(42)

-

(42)

Net increase (decrease) in cash, cash equivalents
and restricted cash 


8,102

631

8,733


(5,723)

(115)

(5,838)


6,370

148

6,518


949

23

972

Cash, cash equivalents and restricted cash

















  At beginning of period


26,928

4,139

31,067


27,211

3,321

30,532


21,488

3,206

24,694


3,206

478

3,684

  At end of period


35,030

4,770

39,800


21,488

3,206

24,694


27,858

3,354

31,212


4,155

501

4,656


















Net cash provided by (used in) operating activities


1,523

(267)

1,256


3,096

340

3,436


2,613

165

2,778


389

25

414

Less: Capital expenditures


(3,378)

(23)

(3,401)


(11,370)

(20)

(11,390)


(7,307)

(42)

(7,349)


(1,090)

(6)

(1,096)

Free cash flow


(1,855)

(290)

(2,145)


(8,274)

320

(7,954)


(4,694)

123

(4,571)


(701)

19

(682)


















Note: Baidu excl. iQIYI represents Baidu, Inc. minus iQIYI's consolidated cash flows.














 

 

 

Baidu, Inc. 

Reconciliations of Non-GAAP Financial Measures to the Nearest Comparable GAAP Measures  

(In millions except for per ADS information, unaudited)




















Three months ended 


Three months ended 


Three months ended 


Three months ended 



September 30, 2025 (RMB)


June 30, 2026 (RMB)


September 30, 2026 (RMB)


September 30, 2026 (US$)



Baidu
General
Business

iQIYI

Baidu,
Inc.


Baidu
General
Business

iQIYI

Baidu,
Inc.


Baidu
General
Business

iQIYI

Baidu,
Inc.


Baidu
General
Business

iQIYI

Baidu,
Inc.

Operating income (loss)


(14,971)

(122)

(15,091)


3,131

(105)

3,024


670

(42)

626


100

(6)

93

Add: Share-based compensation expenses


946

98

1,044


637

72

709


965

65

1,030


144

10

154

Add: Amortization and impairment of intangible assets resulting from business combinations


60

2

62


50

2

52


54

2

56


8

-

8

Add: Impairment of long-lived assets


16,190

-

16,190


-

-

-


-

-

-


-

-

-

Operating income (loss) (non-GAAP)


2,225

(22)

2,205


3,818

(31)

3,785


1,689

25

1,712


252

4

255


















Add:  Depreciation of fixed assets and amortization of finance lease right-of-use assets and intangible assets(1)


2,173

52

2,224


2,323

42

2,365


2,739

42

2,781


408

7

415

Adjusted EBITDA


4,398

30

4,429


6,141

11

6,150


4,428

67

4,493


660

11

670


















Net income (loss) attributable to Baidu


(11,121)

(249)

(11,232)


2,453

(287)

2,319


1,481

(173)

1,395


221

(25)

208

Add: Share-based compensation expenses


945

98

989


636

72

669


964

65

995


143

10

148

Add: Amortization and impairment of intangible assets resulting from business combinations


58

2

59


48

2

49


52

2

53


8

-

8

Add: Impairment of long-lived assets


16,190

-

16,190


-

-

-


-

-

-


-

-

-

Add: Disposal gain


(101)

-

(101)


(26)

-

(26)


(29)

-

(29)


(4)

-

(4)

Add: Impairment of long-term investments


97

-

97


464

-

464


170

21

180


25

3

27

Add: Fair value loss (gain) of long-term investments and exchangeable bonds


279

1

279


(1,073)

3

(1,072)


(712)

58

(683)


(106)

9

(102)

Add: Reconciling items on equity method investments(2)


15

-

15


82

-

82


491

-

491


73

-

73

Add: Tax effects on non-GAAP adjustments(3)


(2,526)

-

(2,526)


88

-

88


(7)

-

(7)


(1)

-

(1)

Net income (loss) attributable to Baidu (non-GAAP)


3,836

(148)

3,770


2,672

(210)

2,573


2,410

(27)

2,395


359

(3)

357


















Diluted earnings (loss) per ADS




(33.88)




5.74




4.35




0.65

Add:  Accretion of the redeemable noncontrolling interests




0.75




0.74




(0.49)




(0.07)

Add:  Non-GAAP adjustments to earnings per ADS




44.25




0.74




2.92




0.43

Diluted earnings per ADS (non-GAAP)




11.12




7.22




6.78




1.01


















(1) This represents amortization of intangible assets excluding those resulting from business combinations.

(2) This represents Baidu's share of equity method investments for other non-GAAP reconciling items, amortization and impairment of intangible assets not on the investee'sbooks, accretion of their redeemable noncontrolling interests, and the gain or loss associated with the issuance of shares by the
investees at a price higher or lower than the carrying value per share.

(3) This represents tax impact of all non-GAAP adjustments.

 

 

 

Information Provided by PR Newswire [Disclaimer]
14:36
HKEX Launches Offshore RMB Bond Index

  • First HKEX branded fixed-income index, tracking the performance of Dim Sum bonds issued in Hong Kong
  • Collaboration with Bloomberg Indices supports index administration and commercialisation

HONG KONG, Nov. 16, 2026 /PRNewswire/ -- Hong Kong Exchanges and Clearing Limited (HKEX) is today (Monday) pleased to announce the launch of the HKEX Offshore RMB Bond Index. The index is the first HKEX branded fixed-income index and Hong Kong's first benchmark for Dim Sum bonds1 issued in the city. By providing investors with a transparent and representative market reference and supporting product innovation, the new index advances HKEX's ongoing commitment to developing Hong Kong's offshore RMB ecosystem.

HKEX has collaborated with Bloomberg — a global leader in financial data, information and index — to support the administration, calculation and commercialisation of the index. Bloomberg Index Services Limited (BISL) will serve as index administrator and calculation agent, supported by Bloomberg's fixed-income pricing and analytics capabilities. HKEX and Bloomberg will also collaborate on the development of a co-branded suite of offshore RMB bond indices for passive and active investment strategies, benchmarking and market analysis. Many asset managers have expressed interest in developing investment products, including ETFs and index funds, based on the benchmarks.

HKEX Chief Executive Officer, Bonnie Y Chan, said: "Hong Kong is the world's leading offshore RMB financial hub, and the launch of the HKEX Offshore RMB Bond Index is a significant step forward in advancing its fixed-income market from an issuance centre towards an ecosystem with greater depth, liquidity and investability. By establishing a transparent and widely recognised benchmark anchored in Hong Kong's market infrastructure, we are supporting greater visibility and investability of offshore RMB assets, encouraging broader market participation and further advancing the internationalisation of the RMB. We are delighted to collaborate with Bloomberg, whose global index expertise and market reach will help broaden access to and deepen participation in the offshore RMB bond market."

Bloomberg Asia-Pacific Chairman, Bing Li, said: "Ongoing RMB internationalisation offers significant opportunities for Hong Kong to further strengthen its role as a leading global financial centre and offshore RMB hub. The development of the Dim Sum bond market is an important part of this journey, connecting global investors with RMB-denominated assets. Bloomberg is proud to collaborate with HKEX through these new indices, as we continue to support Hong Kong and its capital markets with pride."

Eligible securities for the HKEX Offshore RMB Bond Index comprise offshore RMB-denominated Treasury, government-related and corporate debt securities that are listed on the Stock Exchange of Hong Kong (SEHK) and/or lodged with the Central Moneymarkets Unit (CMU) and satisfy the inclusion criteria set out in the index methodology.

As of 30 September 2026, offshore RMB bond issuance has exceeded RMB 590 billion this year. Meanwhile, total bond issuance on HKEX year-to-date has risen 18.6% compared with last year's full-year total. Since 2024, Hong Kong has consistently accounted for more than half of all exchange-listed offshore RMB bonds globally. 

The launch of the new index will help build on this strong primary issuance franchise, supporting greater product innovation in the secondary market and broaden investor participation, whilst increasing the visibility of bonds issued through Hong Kong's market infrastructure. The index will serve as the parent index for a co-branded index suite for future offshore RMB bond ETFs, index funds and other investment products, enabling institutional and retail investors to allocate more efficiently to offshore RMB assets.

The initiative supports the strategic direction set out in Hong Kong's five-year development plan, including priorities for offshore RMB business, product innovation, and market infrastructure, supporting Hong Kong's leading role as an international asset management and wealth management centre.

Further information on the index methodology and statistics is available on the HKEX website.

Note:
1.  Dim Sum bonds are RMB-denominated bonds issued outside the Chinese Mainland. 

About HKEX

Hong Kong Exchanges and Clearing Limited (HKEX) is a publicly-traded company (HKEX Stock Code: 388) and one of the world's leading global exchange groups, offering a range of equity, derivative, commodity, fixed income and other financial markets, products and services, including the London Metal Exchange.

As a superconnector and gateway between East and West, HKEX facilitates the two-way flow of capital, ideas and dialogue between China and the rest of the world, through its pioneering Connect schemes, increasingly diversified product ecosystem and its deep, liquid and international markets.

HKEX is a purpose-led organisation which, across its business and through the work of HKEX Foundation, seeks to connect, promote and progress its markets and the communities it supports for the prosperity of all.

www.hkexgroup.com 

Information Provided by PR Newswire [Disclaimer]
14:16
Akeso's Gumokimab (IL-17A) Receives NMPA Approval for Active Ankylosing Spondylitis

HONG KONG, Nov. 16, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for gumokimab, its self-developed IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS). Active AS marks the second approved indication for gumokimab. In June 2026, gumokimab received approval in China for moderate-to-severe plaque psoriasis.

The AS approval is supported by the positive results of the pivotal Phase 3 registration study AK111-303. The study met all pre-specified efficacy endpoints, demonstrating that gumokimab provides rapid, robust, and sustained relief of AS symptoms while significantly improving disease activity, physical function, and quality of life.

Ankylosing spondylitis is a chronic inflammatory disease that primarily affects the sacroiliac joints, spine, and peripheral joints. In severe cases, it can result in spinal deformity and functional impairment, substantially impacting patients' quality of life. IL-17A is a key pro-inflammatory cytokine implicated in the pathogenesis of autoimmune diseases such as psoriasis and ankylosing spondylitis. Gumokimab binds specifically and with high affinity to human IL-17A, blocking its interaction with IL-17 receptor A (IL-17RA) expressed on T cells, natural killer cells, and antigen-presenting cells, thereby inhibiting the downstream inflammatory cascade.

Professor Rong Mu, Principal Investigator of AK111-303 and Professor at Peking University Third Hospital, stated: "Clinical management of this disease continues to present significant challenges, and current treatment options do not fully address patients' needs regarding depth of response, long-term disease control, and accessibility. The positive results from the pivotal Phase 3 AK111-303 study demonstrated that gumokimab not only consistently achieved the core efficacy endpoints of ASAS20 and ASAS40 and rapidly improved symptoms such as pain and stiffness, but also delivered clear benefits in physical function and quality of life. We look forward to gumokimab becoming an important new treatment option in clinical practice, helping more patients achieve durable disease control, delay structural damage, and regain a higher quality of life."

Dr. Michelle Xia, Founder, Chairwoman, President and Chief Executive Officer of Akeso, commented: "We extend our sincere thanks to the investigators, study teams, and patients who participated in the AK111-303 trial. Their contributions have made this additional treatment option available to patients with AS in China. Substantial unmet medical needs persist in the global autoimmune disease landscape. Akeso continues to advance an expanding and differentiated portfolio of innovative therapies in this field: ebdarokimab (IL-12/IL-23) and gumokimab (IL-17A) are now both approved and available commercially; manfidokimab (IL-4Rα) has multiple indications progressing in late-stage development; and the first-in-class IL-4Rα/ST2 bispecific antibody AK139 is undergoing broader clinical evaluation across several indications. We remain committed to advancing these programs to expand treatment options for patients with autoimmune diseases, and to continue to innovate in this critical therapeutic area."

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.

Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.

Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

Information Provided by PR Newswire [Disclaimer]
12:00
Pony.ai and Toyota Launch Fully Driverless Commercial Services with Gen-7 bZ4X Robotaxi

The ‌collaboratively developed model begins service in Guangzhou, as the companies work toward deploying around 1,000 bZ4X robotaxis across major Chinese cities.

GUANGZHOU, China, Nov. 16, 2026 /PRNewswire/ -- Pony AI Inc. ("Pony.ai") (NASDAQ: PONY; HKEX: 2026), a global leader in the large-scale commercialization of autonomous driving technology, and Toyota today announced the launch of fully driverless commercial services with their ‌collaboratively developed bZ4X Robotaxi.

One of Pony.ai's three seventh-generation ("Gen-7") Robotaxi models, the bZ4X Robotaxi has officially joined the company's fully driverless commercial fleet in Guangzhou. The companies are also testing the model and preparing for deployment in other major Chinese cities.

Pony.ai and Toyota have collaborated on multiple generations of Robotaxis since 2019, and have brought Robotaxi services to Beijing, Shanghai, Guangzhou and Shenzhen. In 2023, Pony.ai, Toyota Motor China and GAC Toyota decided to establish a joint venture with an investment of more than RMB 1 billion to accelerate the mass production and commercial deployment of Robotaxis.

The bZ4X Robotaxi launch marks a major milestone in the partnership, bringing the Gen-7 model from vehicle development and mass production through extensive testing and validation to commercial deployment. The first mass-produced vehicle rolled off the line in February 2026. With production ramping up, the companies are progressing toward their planned deployment of around 1,000 bZ4X Robotaxis across major cities in China.

"Bringing the bZ4X Robotaxi into commercial service demonstrates what can be achieved by combining Pony.ai's proven Level 4 autonomous driving technology with Toyota's world-class vehicle engineering and manufacturing expertise," said Dr. Luyi Mo, Vice President of Pony.ai. "Building on our long-standing partnership, we look forward to expanding deployment and making safe, reliable driverless mobility accessible to more riders."

Passengers in Guangzhou can now hail the bZ4X Robotaxi 24 hours a day through the PonyPilot app or Pony.ai's mini-programs on partner platforms, including WeChat and Alipay. The addition of the new model will further expand Pony.ai's commercial fleet, improving vehicle availability and operational efficiency to meet growing demand for everyday mobility.

The Gen-7 bZ4X Robotaxi, ‌collaboratively developed by Pony.ai and Toyota, offers an enhanced passenger experience, featuring Bluetooth-enabled vehicle unlocking, an intelligent voice assistant, in-car entertainment and personalized climate controls. Further refinements to the autonomous driving system enable smoother acceleration, braking and cornering, creating a more comfortable ride.

The bZ4X Robotaxi was developed from the ground up for Level 4 autonomous driving. With years of experience in autonomous driving technology development, validation and commercial operations, Pony.ai worked closely with Toyota on critical vehicle engineering requirements, including redundancy and fail-operational capabilities, to support safe and reliable fully driverless operations.

The collaboration between Pony.ai and Toyota extends beyond vehicle development and production to fleet operations and maintenance. Combining Pony.ai's experience in operating large-scale autonomous fleets and Toyota's established service and maintenance capabilities, the companies are developing the infrastructure to support fully driverless services at scale, including vehicle maintenance, charging and routine fleet servicing.

About Pony AI Inc.

Pony AI Inc. is a global leader in achieving large-scale commercialization of autonomous mobility. Leveraging its vehicle-agnostic Virtual Driver technology, a full-stack autonomous driving technology that seamlessly integrates Pony.ai's proprietary software, hardware and services, Pony.ai is developing a commercially viable and sustainable business model that enables the mass production and deployment of vehicles across transportation use cases. Founded in 2016, Pony.ai has expanded its presence across China, Europe, Asia, the Middle East and other regions, ensuring widespread access to its advanced technology.

Information Provided by PR Newswire [Disclaimer]
08:00
Innovent Announces Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-squamous Non-Small Cell Lung Cancer

  • The opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is Innovent's first European regulatory milestone; if approved, Zybrivo would expand first-line treatment options for eligible patients with lung cancer in Europe

PALO ALTO, Calif. and SUZHOU, China, Nov. 16, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces it has received its first positive opinion from the CHMP of the European Medicines Agency (EMA). The CHMP recommends marketing authorization of Zybrivo® (sintilimab), in combination with chemotherapy, for adults with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo would provide eligible patients across Europe with access to another first-line treatment option. The positive opinion is supported by results from the Phase 3 ORIENT-11 study (NCT03607539).

"At Innovent, our mission is to empower patients worldwide with affordable, high-quality biopharmaceuticals. The positive CHMP opinion for Zybrivo marks an important regulatory milestone in our international development and brings us a step closer to serving patients in Europe." said Dr. Hui Zhou, Chief R&D Officer of Oncology at Innovent. "Zybrivo has demonstrated clear clinical benefits in the ORIENT-11 study and, if approved, could provide an additional treatment option for patients in Europe with non-squamous non-small cell lung cancer. Building on this progress, we will continue advancing our innovative pipeline and working to bring meaningful medicines to patients around the world."

Following the CHMP's positive opinion, the European Commission is expected to issue a final decision on marketing authorization in the coming months. If approved, the authorization will be valid across all 27 European Union (EU) member states, as well as Iceland, Norway, and Liechtenstein.

Sintilimab, as an immunotherapy, is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1). 

The CHMP recommendation is based on results of ORIENT-11, a randomized, multicenter, double-blind, placebo-controlled Phase 3 study that enrolled 397 adult patients with locally advanced, metastatic or recurrent non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations, regardless of programmed death-ligand 1 (PD-L1) expression. Patients were randomized 2:1 to receive sintilimab or placebo, each in combination with pemetrexed and platinum-based chemotherapy. The primary endpoint was progression-free survival (PFS), assessed by a blinded independent radiological review committee.

In ORIENT-11, sintilimab plus chemotherapy demonstrated a 52% reduction in the hazard of disease progression or death (median PFS: 8.9 vs. 5.0 months) and a 35% reduction in the hazard of death (median overall survival (OS): 24.2 vs. 16.8 months), compared with placebo plus chemotherapy.

These results demonstrate the clinical benefit of sintilimab in combination with chemotherapy and its potential to offer an additional first-line treatment option for eligible patients with advanced non-squamous NSCLC in Europe.

The safety profile of sintilimab in combination with chemotherapy was consistent with the known safety profiles of PD-1 inhibitors and the chemotherapy agents used, with no new safety signals identified. Additional details may be found at clinicaltrials.gov, using identifier NCT03607539.

Zybrivo in combination with pemetrexed and platinum-based chemotherapy is indicated for the first line treatment of adult non-squamous non-small cell lung cancer (NSCLC) patients with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and who have:

  • locally advanced NSCLC and are not candidates for curative intent surgical resection or chemoradiation, or
  • metastatic NSCLC.

About Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer death in the EU, accounting for about one in five cancer deaths.[1] An estimated 319,000 people in the EU were diagnosed with lung cancer in 2022.[2] Non-small cell lung cancer (NSCLC) is the most common form of the disease, representing 85–90% of all lung cancers.[3]

About Sintilimab
Sintilimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1), a protein that can prevent the immune system from attacking cancer cells, and blocks its interaction with the ligands PD-L1 and PD-L2[4].

Sintilimab has been approved in China for ten indications, covering squamous non-small cell lung cancer, EGFR/ALK wild type non-squamous NSCLC, EGFR tyrosine kinase inhibitor (TKI) treatment failure non-squamous NSCLC, hepatocellular carcinoma, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell cancer, endometrial cancer, colon cancer, renal cell carcinoma and classical Hodgkin's lymphoma. In China, sintilimab has been used to treat approximately 3 million patients[5].

Important Safety Information

Product information for sintilimab will be available from the European Medicines Agency following the European Commission decision.

This information is intended for a global audience. Product indications vary by region.

About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under review by China's National Medical Products Administration (NMPA), 6 assets in phase 3 or pivotal clinical trials, and 20 more molecules in early clinical stage.

Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the high-quality outbound internationalization of China's innovative drug industry.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

(1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).

(2) Ramucirumab Injection (Cyramza®), Selpercatinib Capsules (Retsevmo®), Pirtobrutinib Tablets (Jaypirca®) and abemaciclib (Verzenios®) are products discovered and developed by Eli Lilly.

Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References


[1] European Cancer Information System (ECIS). 2022 new cancer cases and cancer deaths on the rise in the EU. European Commission, Joint Research Centre; September 2023. https://ecis.jrc.ec.europa.eu/cancer-factsheets-eu-27-countries-2022.

[2] European Commission. Estimated age-standardised number of new cases and incidence rates of lung cancer in the European Union in 2022. Knowledge for Policy, based on ECIS data. https://knowledge4policy.ec.europa.eu/dataset/k4p-dataset-77314_en.

[3] European Society for Medical Oncology (ESMO). Non-Small-Cell Lung Cancer: An ESMO Guide for Patients. p. 4. https://dam.esmo.org/image/upload/v1737550922/EN%20%7C%20Non-Small-Cell%20Lung%20Cancer:%20Guide%20for%20Patients.pdf 

[4] Wang J, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs 2019;11(8): 1443-1451. doi: 10.1080/19420862.2019.1654303.

[5] As of November 2026, the cumulative number of patients treated with sintilimab at medical institutions and other platforms.

 

Information Provided by PR Newswire [Disclaimer]
2026-11-14
18:28
亞盛醫藥利生妥®成功納入2026年國家醫保藥品目錄,耐立克®續約

中國蘇州2026年11月14日 /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥(納斯達克代碼:AAPG;香港聯交所代碼:6855)今日宣布,公司兩款原創1類新藥成功納入新版《國家基本醫療保險、生育保險和工傷保險藥品目錄(2026年)》(「國家醫保藥品目錄」),分別為:

  • 利生妥®(利沙托克拉)通過談判首次納入國家醫保藥品目錄,用於既往經過至少包含布魯頓酪氨酸激酶(BTK)抑制劑在內的一種系統治療的成人慢性淋巴細胞白血病(CLL)/小淋巴細胞淋巴瘤(SLL)患者。
  • 耐立克®(奧雷巴替尼)通過重新談判成功續約國家醫保藥品目錄,用於1、對一代和二代酪氨酸激酶抑制劑(TKI)耐藥和/或不耐受的慢性髓細胞白血病(CML)慢性期(-CP)成年患者;2、T315I突變的CML-CP或加速期(-AP)的成年患者。

截至目前,亞盛醫藥兩款高質量全球創新藥的全部獲批適應症均已納入國家醫保藥品目錄,將為更多患者提供更加可及的創新治療選擇。新版國家醫保藥品目錄將於2027年1月1日起正式實施。

利生妥®是亞盛醫藥自主研發的新型口服Bcl-2選擇性抑制劑,通過選擇性抑制Bcl-2蛋白,恢復癌細胞的正常凋亡過程,從而達到治療腫瘤的目的。利生妥®於2025年7月在中國獲批上市,是中國首個上市的國產原創Bcl-2抑制劑。此次利生妥®成功納入新版國家醫保藥品目錄,將大大提升國內CLL/SLL患者的用藥可及性,讓更多患者能夠及時獲得新的治療選擇。

耐立克®是亞盛醫藥自主研發的新型口服第三代BCR-ABL抑制劑,獲國家「重大新藥創制」專項支持,其中國的商業化推廣由亞盛醫藥和信達生物共同負責。耐立克®於2021年11月在中國獲批上市,是中國首個上市的第三代BCR-ABL抑制劑。此次耐立克®成功續約,將持續惠及國內更多CML患者,進一步提升長期用藥的可負擔性與可及性。

亞盛醫藥董事長、CEO楊大俊博士表示:「此次利生妥®成功納入、耐立克®成功續約後,公司兩款原創1類新藥的全部獲批適應症均已納入國家醫保藥品目錄。對患者而言,這意味著創新治療的可及性進一步提升;對企業而言,這是商業化能力和持續創新能力的重要支撐;而從行業角度看,這也是國家醫保政策鼓勵真創新、國產原創新藥價值獲得進一步認可的體現,為企業持續開展源頭創新注入了信心。」

關於亞盛醫藥

亞盛醫藥(納斯達克代碼:AAPG;香港聯交所代碼:6855)是一家綜合性的全球生物醫藥企業,致力於研發、生產和商業化創新藥,以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線,包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克®是中國首個獲批上市的第三代BCR-ABL抑制劑,已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期(CML-CP)和加速期(CML-AP)患者,以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄(NRDL)。目前,亞盛醫藥正在開展耐立克®三項全球注冊III期臨床研究,分別為:獲美國FDA和歐洲EMA許可的評估耐立克®治療新診斷費城染色體陽性急性淋巴細胞白血病(Ph+ ALL)患者POLARIS-1研究;獲美國FDA和歐洲EMA許可的評估耐立克®治療經治CML-CP成年患者的POLARIS-2研究;評估耐立克®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥®已獲中國國家藥品監督管理局(NMPA)批准,用於治療既往至少接受過一種包括布魯頓酪氨酸激酶(BTK)抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤(CLL/SLL)患者。目前,亞盛醫藥正在開展利生妥®四項全球注冊III期臨床研究,分別為:獲美國FDA和歐洲EMA許可的評估利生妥®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究;評估利生妥®一線治療初治CLL/SLL患者的GLORA-2研究;評估利生妥®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究;以及獲美國FDA和歐洲EMA許可的評估利生妥®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力,亞盛醫藥已在全球范圍內進行知識產權布局,並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物制藥公司達成全球合作,同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關系。如需了解更多信息,請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》,以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外,本新聞稿中的所有內容均可能構成前瞻性陳述,包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響,具體內容已在亞盛醫藥向美國證券交易委員會(SEC)提交的文件中詳細說明,包括2026年4月29日提交的20-F表格中截止2025年12月31日的年度報告中的「風險因素」和「關於前瞻性聲明的警示聲明」章節,2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節,以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此,該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷,且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況,亞盛醫藥均無義務更新或修訂任何前瞻性陳述。

Information Provided by PR Newswire [Disclaimer]
14:00
再鼎醫藥宣布呫諾美林曲司氯銨膠囊(I)/(II)/(III)與艾加莫德α注射液(皮下注射)首次納入2026年版國家醫保藥品目錄,擴大核心增長產品可及性

中國上海和美國馬薩諸塞州劍橋市2026年11月14日 /美通社/ -- 再鼎醫藥有限公司(納斯達克股票代碼:ZLAB;香港聯交所股份代號:9688),一家以創新為驅動的全球生物製藥公司,今日宣布,公司在國內的多款商業化產品被納入《國家基本醫療保險、生育保險和工傷保險藥品目錄(2026)》。本次更新包括兩款首次納入產品,擴大了全身型重症肌無力(gMG)患者與精神分裂症治療患者的治療可及性;以及三款續約產品,持續保障了腫瘤和感染性疾病領域的用藥可及性。

再鼎醫藥本次新增或續約納入2026版醫保藥品目錄的產品:

首次納入:

  • 艾加莫德α注射液(皮下注射)(衛力迦®):用於治療乙酰膽鹼受體(AChR)抗體陽性的成人全身型重症肌無力(gMG)患者。
  • 呫諾美林曲司氯銨膠囊(I)/(II)/(III)(凱捷樂®):用於治療成人精神分裂症。

續約產品:

  • 注射用甲苯磺酸奧馬環素(紐再樂®):用於治療社區獲得性細菌性肺炎和急性細菌性皮膚和皮膚結構感染。
  • 瑞派替尼片(擎樂®):用於治療既往接受過3種或以上激酶抑製劑(包括伊馬替尼)的晚期胃腸間質瘤(GIST)成人患者。
  • 瑞普替尼膠囊(奧凱樂®):用於治療ROS1陽性的局部晚期或轉移性非小細胞肺癌(NSCLC)成人患者,以及攜帶神經營養酪氨酸受體激酶(NTRK)融合基因的成人實體瘤患者。

「呫諾美林曲司氯銨膠囊與艾加莫德α注射液(皮下注射)成功納入國家醫保藥品目錄,對再鼎以及我們所服務的患者而言,是一個重要的里程碑,」再鼎醫藥運營合伙人王軼喆博士表示,「這將有助於擴大兩款重要療法的可及性——包括呫諾美林曲司氯銨膠囊用於精神分裂症的創新作用機制,以及艾加莫德α注射液(皮下注射)為全身型重症肌無力患者帶來的給葯便利。連同其他已上市產品的成功續約,我們衷心感謝國家醫保局對創新藥物的持續支持,並將繼續致力於為患者帶來更大獲益。」

2026年版國家醫保藥品目錄將於2027年1月1日起執行。

備註:

凱捷樂®僅作為註冊商標使用

呫諾美林曲司氯銨膠囊(I)/(II)/(III)本次納入2026年版國家醫保藥品目錄,包含以下:(Ⅰ)每粒含酒石酸呫諾美林50mg(按C14H23N3OS計)與曲司氯銨20mg;(Ⅱ)每粒含酒石酸呫諾美林100mg(按C14H23N3OS計)與曲司氯銨20mg;(Ⅲ)每粒含酒石酸呫諾美林125mg(按C14H23N3OS計)與曲司氯銨30mg。均限成人精神分裂症。

*瑞普替尼納入2026年版國家醫保藥品目錄,針對攜帶NTRK融合基因成人實體瘤患者的報銷(醫保支付)範圍,具體為:經充分驗證的檢測方法診斷為攜帶神經營養酪氨酸受體激酶(NTRK)融合基因的成人實體瘤患者,且具有以下情況之一:患有局部晚期或轉移性疾病,或手術切除可能導致嚴重併發症,或既往治療失敗、無滿意替代治療。

關於再鼎醫藥

再鼎醫藥(納斯達克股票代碼:ZLAB;香港聯交所股份代號:9688)是一家以研發為基礎、處於商業化階段的創新型生物製藥公司,總部位於中國和美國。我們致力於通過創新產品的發現、開發和商業化解決腫瘤、免疫、神經科學和感染性疾病領域未被滿足的巨大醫療需求。我們的目標是利用我們的能力和資源為人類健康帶來積極影響。

有關再鼎醫藥的更多信息,請訪問 www.zailaboratory.com 或關注公司官微:再鼎醫藥。

再鼎醫藥前瞻性聲明

本新聞稿包含關於我們對再鼎醫藥未來預期、計劃以及前景的前瞻性陳述,包括但不限於有關艾加莫德皮下注射、呫諾美林曲司氯銨、瑞派替尼、瑞普替尼和甲苯磺酸奧馬環素的獲益與潛力,以及在中國治療全身型重症肌無力(gMG)、精神分裂症、非小細胞肺癌(NSCLC)、某些實體瘤、社區獲得性細菌性肺炎和急性細菌性皮膚和皮膚結構感染的陳述。除對過往事實的陳述外,本新聞稿中包含的所有陳述均為前瞻性陳述,可以通過諸如「旨在」、「預計」、「認為」、「有可能」、「估計」、「預期」、「預測」、「目標」、「打算」、「可能」、「計劃」、「可能的」、「潛在」、「將」、「將會」等詞彙及其他類似表述加以識別。前瞻性陳述並非對未來表現的承諾或保證,乃基於我們截至本新聞稿發布之日的預期和假設,並且受固有的不確定性、風險及可能與前瞻性陳述所預期的情況存在重大差異的情勢變更的影響。實際結果可能受各多種重要因素的影響存在重大差異,該等因素包括但不限於:(1) 我們成功商業化已獲批產品並從中產生收入的能力;(2) 我們為運營和業務活動獲取資金的能力;(3) 我們候選產品臨床及臨床前開發的結果;(4) 相關監管機構對我們候選產品作出審批決定的內容和時間;(5) 與在中國營商有關的風險;以及 (6) 我們向美國證券交易委員會(SEC)提交的最新年報和季報及其他報告中指出的其他因素。除法律要求之外,無論出於新信息、未來事件或其他原因,我們均無義務更新或修訂任何前瞻性陳述。如需查閱公司向 SEC 提交的文件,請訪問公司網站 www.zailaboratory.com 和 SEC 網站 www.SEC.gov。

Information Provided by PR Newswire [Disclaimer]
13:38
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

SHANGHAI and CAMBRIDGE, Mass, Nov. 14, 2026 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country's 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for gMG and schizophrenia, and three renewals, which maintain access across oncology and infectious disease.

Zai Lab Products Newly Added or Renewed in 2026 NRDL:

First-time listings:

  • VYVGART Hytrulo® (efgartigimod alfa, subcutaneous injection): for the treatment of adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG).
  • KarXT (xanomeline and trospium chloride capsules): for the treatment of schizophrenia in adults.

Renewals:

  • NUZYRA® (omadacycline for injection): for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
  • QINLOCK® (ripretinib tablets): for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
  • AUGTYRO® (repotrectinib capsules): for the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), and adult patients with solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.

"The inclusion of KarXT and VYVGART Hytrulo in the NRDL represents an important milestone for Zai Lab and the patients we serve," said Dr. Yizhe Wang, Zai Lab Operating Partner. "These listings will help broaden access to two important therapies, including KarXT's novel mechanism of action for schizophrenia and the convenience of VYVGART Hytrulo's subcutaneous administration for patients with gMG. Together with the renewal of our other listed products, we are grateful to the National Healthcare Security Administration for its continued support of innovative medicines and remain committed to delivering greater benefit to patients."

The 2026 National Reimbursement Drug List will take effect on January 1, 2027.

Notice:

*xanomeline and trospium chloride capsules included in the 2026 NRDL covers the following specifications: (I) xanomeline tartrate 50 mg (calculated as C14H23N3OS) and trospium chloride 20 mg per capsule; (II) xanomeline tartrate 100 mg (as C14H23N3OS) and trospium chloride 20 mg per capsule; (III) xanomeline tartrate 125 mg (as C14H23N3OS) and trospium chloride 30 mg per capsule. All are indicated for schizophrenia in adults.

*For AUGTYRO® included in the 2026 NRDL, the reimbursement scope for adult patients with NTRK gene fusion-positive solid tumors is specifically: adult patients diagnosed, by a well-validated testing method, with solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and who meet one of the following conditions: having locally advanced or metastatic disease, or for whom surgical resection is likely to result in severe complications, or who have failed prior treatment or have no satisfactory alternative treatment options.

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.linkedin.com/company/zai-lab or https://x.com/ZaiLab_Global.

Zai Lab Forward-Looking Statements

This press release contains forward-looking statements about our future expectations, plans, and prospects for Zai Lab, including, without limitation, statements relating to the benefits and potential of VYVGART Hytrulo, KarXT, QINLOCK, AUGTYRO, and NUZYRA and the treatment of gMG, schizophrenia, NSCLC, certain solid tumors, and community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in China. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and can be identified by terms such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "will," "would," and similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither promises nor guarantees of future performance, and are based on our expectations and assumptions as of the date of this press release, and are subject to inherent uncertainties, risks, and changes in circumstances that may cause actual results to differ materially from those anticipated. Actual results may differ materially as a result of various important factors, including but not limited to: (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to obtain funding for our operations and business activities; (3) the results of clinical and preclinical development of our product candidates; (4) the content and timing of decisions made by the relevant regulatory authorities regarding our product candidates; (5) risks related to doing business in China; and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. For access to the company's filings with the SEC, please visit www.zailaboratory.com and the SEC's website at www.SEC.gov.

Information Provided by PR Newswire [Disclaimer]
11:48
Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List

PALO ALTO, Calif. and SUZHOU, China, Nov. 14, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announced that seven innovative products of Innovent were successfully included in the updated National Reimbursement Drug List (2026) (the "NRDL").

Products included in the NRDL for the first time include mazdutide (a GCG/GLP-1 dual receptor agonist), PECONDLE® (picankibart injection, an IL-23p19 inhibitor), TABOSUN® (Ipilimumab N01 injection, a CTLA-4 inhibitor), and Vanflyta® (quizartinib, a Type II FLT3 inhibitor). Products with newly added indications included in the NRDL comprise TYVYT® (sintilimab injection, an anti-PD-1 monoclonal antibody) and Jaypirca® (pirtobrutinib, a non-covalent BTK inhibitor); and SINTBILO® (tafolecimab injection, a fully human PCSK9 monoclonal antibody) was successfully renewed. The updated NRDL will officially take effect from January 1, 2027.

Dr. Michael Yu, the Founder, Chairman of the Board and CEO of Innovent, stated: "We are highly pleased that the seven innovative drugs of Innovent have been successfully included in the National Reimbursement Drug List this time, covering disease areas with heavy societal burdens such as oncology (colon cancer, renal cancer, and hematological malignancies), cardiovascular and metabolic diseases, as well as autoimmune diseases. The inclusion of the innovative drugs in the NRDL will further enhance the accessibility and affordability for patients, allowing more of the public to benefit. With this, the lineup of Innovent's innovative drugs covered by the NRDL has expanded to 17, cumulatively benefiting over 20 million patients, and continuously fortifying the medication safeguards for patients through innovative achievements. Adhering to our corporate mission to 'empower patients worldwide with affordable, high-quality biopharmaceuticals', Innovent consistently places patient needs at its core, actively responds to the strategic call of 'Healthy China 2030', facilitates the construction of a universal health safeguard system through practical actions, and promotes the continuous improvement of people's health. We will actively cooperate with the implementation of medical insurance policies, ensuring that high-quality innovative medicines benefit countless households faster and more broadly.

Mazdutide
Innovent entered into an exclusive license agreement with Eli Lilly and Company for the development and commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity.

Mazdutide is newly included in the updated NRDL for: type 2 diabetes in adults. Mazdutide is the first and only approved GCG/GLP-1 dual receptor agonist globally. This inclusion into the NRDL will provide a better option for the comprehensive management of Chinese patients with type 2 diabetes.

PECONDLE® (picankibart injection)

Picankibart (IBI112) is a recombinant anti-interleukin-23p19 subunit (IL-23p19) antibody injection. It is a monoclonal antibody with independent intellectual property rights independently developed by Innovent, which specifically binds to the IL-23p19 subunit. By preventing IL-23 from binding to cell surface receptors, it blocks the IL-23 receptor-mediated signaling pathway to exert anti-inflammatory effects.

Picankibart injection is newly included in the updated NRDL for: adult patients with moderate to severe plaque psoriasis eligible for systemic therapy. Picankibart is the first and only domestic IL-23p19 inhibitor. It is also the first product among global IL-23p19 drugs with the same target to achieve a PASI 90 response rate exceeding 80% at 16 weeks in a Phase III registrational clinical trial, and possesses the longest maintenance dosing interval in its class (once every 12 weeks). This inclusion in the NRDL will effectively improve treatment convenience and patient compliance.

TABOSUN® (Ipilimumab N01 injection)

Ipilimumab N01 (IBI310) is a recombinant fully human anti-CTLA-4 monoclonal antibody independently developed by Innovent. Ipilimumab N01 can specifically bind to CTLA-4, thereby blocking CTLA-4-mediated T cell inhibition, promoting the activation and proliferation of T cells, enhancing the tumor immune response, and achieving anti-tumor effects.

Ipilimumab N01 injection is newly included in the updated NRDL for: use in combination with sintilimab for the neoadjuvant treatment of patients with resectable stage IIB-III microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colon cancer. As the world's only approved dual-immunotherapy combination regimen for this indication, it synergistically activates anti-tumor immunity through both the CTLA-4 and PD-1 pathways, providing patients with a short-course, chemotherapy-free, and 0-recurrence neoadjuvant treatment option, which fills the dual gaps in clinical practice and medical insurance coverage.

VANFLYTA® (quizartinib)

Quizartinib is an oral, highly potent type II FLT3 inhibitor that targets FLT3-ITD mutations, developed by Daiichi Sankyo and solely commercialized in Mainland China by Innovent.

Quizartinib is newly included in the updated NRDL for: newly diagnosed acute myeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive as detected by an adequate validated diagnostic test. It has effectively filled the gap in the NRDL coverage, addressed the shortcomings in clinical treatment, and practically alleviated the treatment burden of AML patients.

TYVYT® (sintilimab injection)

Sintilimab injection (IBI308) is an innovative PD-1 inhibitor drug jointly developed by Innovent and Eli Lilly and Company.

Sintilimab has been approved in China for ten indications, covering squamous non-small cell lung cancer, non-squamous non-small cell lung cancer (including EGFR/ALK wild type non-squamous NSCLC and EGFR-TKI treatment failed non-squamous NSCLC), hepatocellular carcinoma, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell cancer, endometrial cancer, colon cancer, renal cell carcinoma and classical Hodgkin's lymphoma.

Two additional indications have been successfully included in the updated NRDL: sintilimab in combination with ipilimumab N01 as neoadjuvant treatment for patients with resectable stage IIB–III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer; and sintilimab in combination with fruquintinib for patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) therapy and have not received programmed death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor therapy in the first-line setting. The NRDL inclusion of two indications further broadens reimbursement coverage for the neoadjuvant treatment of patients with MSI-H/dMMR colon cancer and the combination treatment of targeted therapy and immunotherapy for second-line renal cell carcinoma patients.

Jaypirca® (pirtobrutinib)

Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor developed by Eli Lilly and Company, for which Innovent is responsible for the exclusive commercialization in Mainland China. In preclinical studies, pirtobrutinib is 300 times more selective for BTK versus 98% of other kinases tested[i]. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)[ii],[iii].

Pirtobrutinib was approved in China in October 2024 and was officially included in the NRDL on January 1, 2026. One additional indication has now been successfully included in the updated NRDL: treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior systemic therapy that included a Bruton's tyrosine kinase (BTK) inhibitor. This further broadens NRDL coverage for the treatment of this disease.

SINTBILO® (tafolecimab injection)

Tafolecimab injection (IBI306) is the first domestic fully human anti-PCSK9 monoclonal antibody independently developed by Innovent. By inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) in blood plasma, it blocks its binding to the low-density lipoprotein receptor(LDLR), thereby preventing the endocytosis and degradation of LDLR, increasing the expression level and quantity of LDLR on the cell surface, enhancing the reuptake of low-density lipoprotein cholesterol (LDL-C) by LDLR, and decreasing the circulating LDL-C level, ultimately achieving the purpose of lowering blood lipids.

Tafolecimab was approved for marketing in August 2023 and was officially included in the NRDL on January 1, 2025. This successful contract renewal will further alleviate the financial burden on patients, enabling this advanced lipid-lowering therapy to benefit a broader patient population.

Looking towards the goals of the China's "15th Five-Year Plan", Innovent will remain committed to innovation-driven development, focus on the unmet clinical needs in the field of major diseases, and continuously advance the R&D, manufacturing and commercialization of high-quality innovative drugs, to serve people's lives and health with more innovative achievements, and contribute to the high-quality development of the biopharmaceutical industry and the building of a "Healthy China".

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NMPA review, 6 assets in phase 3 or pivotal clinical trials, and 20 more molecules in early clinical stage.

Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the high quality outbound internationalization of China's innovative drug industry.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: (1)Innovent does not recommend the use of any unapproved drug (s)/indication (s).

(2) Ramucirumab Injection (Cyramza®), Selpercatinib Capsules (Retsevmo®), Pirtobrutinib Tablets (Jaypirca®) and abemaciclib (Verzenios®) are products discovered and developed by Eli Lilly.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

References

[i] Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892-901. doi:10.1016/S0140-6736(21)00224-5

[ii] Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79. Published 2020 Jun 17. doi:10.1186/s13045-020-00914-1

[iii] Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40. Published 2021 Mar 6. doi:10.1186/s13045-021-01049-7

 

Information Provided by PR Newswire [Disclaimer]